David  Hickey net worth and biography

David Hickey Biography and Net Worth

Dave Hickey serves as executive vice president and president of the Life Sciences segment of BD (Becton, Dickinson and Company), a leading global medical technology company headquartered in Franklin Lakes, New Jersey. In this role, he oversees the global operational, commercial and financial performance of the businesses that comprise the Life Sciences segment that span along the continuum of discovery, translational, diagnostics and therapy selection, including Biosciences, Integrated Diagnostic Solutions and Point-of-Care.

Hickey brings more than 30 years of experience in medical technology. He joined BD in 2014 as vice president and general manager for the Clinical Microbiology business. In 2016, he was promoted to president of the Diagnostics Systems business, and in 2019, to worldwide president of the newly formed Integrated Diagnostic Solutions unit, which brought together the strengths of the Diagnostic Systems and Preanalytical Systems businesses.

Under Hickey’s leadership, IDS became instrumental in the global fight against SARS-CoV-2 (COVID-19), overseeing the development, launch, manufacturing and distribution of critical molecular and rapid point-of-care tests as well as critical swabs and viral transport systems. Today, he leads a team of more than 18,000 associates united in a vision to shape the future of healthcare through the translation and delivery of innovative technologies to advance life sciences medical research and create impactful diagnostics solutions for customers and the patients they serve.

Prior to BD, Hickey spent 22 years with Siemens Healthcare Diagnostics in multiple positions of increasing responsibility, including his last four years as CEO of its Central Laboratory Business Unit.

Hickey is an active participant on the boards of directors for AdvaMedDx, Greater Baltimore Committee, Johns Hopkins Bloomberg School of Public Health, and the University of Maryland, Baltimore (UMB) Health Sciences Research Park.

Hickey earned his Medical Laboratory Sciences degree in Clinical Biochemistry from the University of Manchester in the UK.

What is David Hickey's net worth?

The estimated net worth of David Hickey is at least $1.03 million as of August 11th, 2023. Mr. Hickey owns 4,199 shares of Becton, Dickinson and Company stock worth more than $1,033,794 as of February 24th. This net worth approximation does not reflect any other investments that Mr. Hickey may own. Additionally, Mr. Hickey receives an annual salary of $1,110,000.00 as EVP at Becton, Dickinson and Company. Learn More about David Hickey's net worth.

How old is David Hickey?

Mr. Hickey is currently 61 years old. There are 7 older executives and no younger executives at Becton, Dickinson and Company. Learn More on David Hickey's age.

What is David Hickey's salary?

As the EVP of Becton, Dickinson and Company, Mr. Hickey earns $1,110,000.00 per year. There are 4 executives that earn more than Mr. Hickey. The highest earning executive at Becton, Dickinson and Company is Mr. Thomas E. Polen Jr., President, CEO & Chairman, who commands a salary of $3,460,000.00 per year. Learn More on David Hickey's salary.

How do I contact David Hickey?

The corporate mailing address for Mr. Hickey and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on David Hickey's contact information.

Has David Hickey been buying or selling shares of Becton, Dickinson and Company?

David Hickey has not been actively trading shares of Becton, Dickinson and Company during the past quarter. Most recently, David Hickey sold 2,974 shares of the business's stock in a transaction on Friday, August 11th. The shares were sold at an average price of $277.85, for a transaction totalling $826,325.90. Following the completion of the sale, the executive vice president now directly owns 4,199 shares of the company's stock, valued at $1,166,692.15. Learn More on David Hickey's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, insiders at the medical instruments supplier sold shares 5 times. They sold a total of 7,737 shares worth more than $2,065,570.22. The most recent insider tranaction occured on November, 28th when EVP Richard Byrd sold 2,156 shares worth more than $514,141.32. Insiders at Becton, Dickinson and Company own 0.3% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 11/28/2023.

David Hickey Insider Trading History at Becton, Dickinson and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2023Sell2,974$277.85$826,325.904,199View SEC Filing Icon  
8/15/2022Sell475$265.00$125,875.003,331View SEC Filing Icon  
5/6/2022Sell475$256.00$121,600.003,806View SEC Filing Icon  
See Full Table

David Hickey Buying and Selling Activity at Becton, Dickinson and Company

This chart shows David Hickey's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $246.20
Low: $242.90
High: $246.60

50 Day Range

MA: $239.92
Low: $234.30
High: $247.73

2 Week Range

Now: $246.20
Low: $228.62
High: $287.32


992,662 shs

Average Volume

1,564,688 shs

Market Capitalization

$71.13 billion

P/E Ratio


Dividend Yield